FDA News Briefs for April 27, 2020

The Food and Drug Administration (FDA) approved these new therapies last week:Trodelvy (sacituzumab-govitecan-hziy; Immunomedics Inc.)On April 22, 2020, the FDA approved a biologics license application (BLA) for Trodelvy, a Trop-2-directed antibody and topoisomerase...